National Bank of Canada’s Takeda Pharmaceutical TAK Stock Holding History

National Bank of Canada’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$32.2K	Sell	1,739 -4,987	-74%	-$87.5K	﹤0.01%	2075
2025 Q4	$105K	Buy	6,726 +1,334	+25%	+$19.1K	﹤0.01%	1767
2025 Q3	$78.9K	Buy	5,392 +281	+5%	+$4.17K	﹤0.01%	1822
2025 Q2	$79K	Buy	5,111 +145	+3%	+$2.14K	﹤0.01%	1849
2025 Q1	$73.8K	Buy	4,966 +429	+9%	+$6.01K	﹤0.01%	1771
2024 Q4	$60.1K	Sell	4,537 -43	-0.9%	-$591	﹤0.01%	1887
2024 Q3	$65.1K	Hold	4,580	–	–	﹤0.01%	1635
2024 Q2	$59.2K	Hold	4,580	–	–	﹤0.01%	1640
2024 Q1	$60.6K	Hold	4,580	–	–	﹤0.01%	1690
2023 Q4	$65.6K	Hold	4,580	–	–	﹤0.01%	1683
2023 Q3	$69.3K	Hold	4,580	–	–	﹤0.01%	1713
2023 Q2	$71.8K	Hold	4,580	–	–	﹤0.01%	1679
2023 Q1	$75.5K	Hold	4,580	–	–	﹤0.01%	1592
2022 Q4	$71.4K	Hold	4,580	–	–	﹤0.01%	1650
2022 Q3	$59K	Buy	+4,580	New	+$63.7K	﹤0.01%	1646

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

National Bank of Canada's TAK Position: Q1 2026 in Review

National Bank of Canada reduced its Takeda Pharmaceutical (TAK) stake by 74% in Q1 2026, selling an estimated $87.5K and leaving 1,739 shares worth $32.2K. The position accounts for ﹤0.01% of the portfolio, ranked #2075.

National Bank of Canada first reported a position in TAK in Q3 2022 and has held it in 15 quarters since. The position peaked at $105K in Q4 2025. 359 funds tracked by Wall St. Rank hold TAK as of Q1 2026.

National Bank of Canada held 1,739 shares of Takeda Pharmaceutical worth $32.2K as of Q1 2026.
National Bank of Canada sold 4,987 Takeda Pharmaceutical shares in Q1 2026, an estimated $87.5K.
Takeda Pharmaceutical made up ﹤0.01% of National Bank of Canada's portfolio in Q1 2026, its #2075 holding.
National Bank of Canada first reported a position in Takeda Pharmaceutical in Q3 2022 and has held it in 15 quarters since.
National Bank of Canada's Takeda Pharmaceutical position peaked at $105K in Q4 2025.
359 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q1 2026.

Based on National Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.